366 related articles for article (PubMed ID: 10626357)
1. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
2. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.
Vaisman A; Lim SE; Patrick SM; Copeland WC; Hinkle DC; Turchi JJ; Chaney SG
Biochemistry; 1999 Aug; 38(34):11026-39. PubMed ID: 10460158
[TBL] [Abstract][Full Text] [Related]
3. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
4. The role of DNA mismatch repair in platinum drug resistance.
Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
[TBL] [Abstract][Full Text] [Related]
5. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
6. Protein interactions with platinum-DNA adducts: from structure to function.
Chaney SG; Campbell SL; Temple B; Bassett E; Wu Y; Faldu M
J Inorg Biochem; 2004 Oct; 98(10):1551-9. PubMed ID: 15458816
[TBL] [Abstract][Full Text] [Related]
7. Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro.
Bassett E; Vaisman A; Havener JM; Masutani C; Hanaoka F; Chaney SG
Biochemistry; 2003 Dec; 42(48):14197-206. PubMed ID: 14640687
[TBL] [Abstract][Full Text] [Related]
8. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta.
Vaisman A; Masutani C; Hanaoka F; Chaney SG
Biochemistry; 2000 Apr; 39(16):4575-80. PubMed ID: 10769112
[TBL] [Abstract][Full Text] [Related]
9. Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta.
Bassett E; Vaisman A; Tropea KA; McCall CM; Masutani C; Hanaoka F; Chaney SG
DNA Repair (Amst); 2002 Dec; 1(12):1003-16. PubMed ID: 12531010
[TBL] [Abstract][Full Text] [Related]
10. The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta.
Vaisman A; Chaney SG
J Biol Chem; 2000 Apr; 275(17):13017-25. PubMed ID: 10777605
[TBL] [Abstract][Full Text] [Related]
11. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
Chaney SG; Campbell SL; Bassett E; Wu Y
Crit Rev Oncol Hematol; 2005 Jan; 53(1):3-11. PubMed ID: 15607931
[TBL] [Abstract][Full Text] [Related]
12. One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes.
Yamada K; Kato N; Takagi A; Koi M; Hemmi H
Anal Bioanal Chem; 2005 Aug; 382(7):1702-7. PubMed ID: 15959768
[TBL] [Abstract][Full Text] [Related]
13. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.
Nehmé A; Baskaran R; Nebel S; Fink D; Howell SB; Wang JY; Christen RD
Br J Cancer; 1999 Mar; 79(7-8):1104-10. PubMed ID: 10098743
[TBL] [Abstract][Full Text] [Related]
14. The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells.
Perego P; Gatti L; Caserini C; Supino R; Colangelo D; Leone R; Spinelli S; Farrell N; Zunino F
J Inorg Biochem; 1999 Oct; 77(1-2):59-64. PubMed ID: 10626355
[TBL] [Abstract][Full Text] [Related]
15. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
16. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.
Rennicke A; Voigt W; Mueller T; Fruehauf A; Schmoll HJ; Beyer C; Dempke W
Anticancer Res; 2005; 25(2A):1147-55. PubMed ID: 15868958
[TBL] [Abstract][Full Text] [Related]
17. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells.
Gibbons GR; Kaufmann WK; Chaney SG
Carcinogenesis; 1991 Dec; 12(12):2253-7. PubMed ID: 1747924
[TBL] [Abstract][Full Text] [Related]
18. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
19. Polymerization by DNA polymerase eta is blocked by cis-diamminedichloroplatinum(II) 1,3-d(GpTpG) cross-link: implications for cytotoxic effects in nucleotide excision repair-negative tumor cells.
Chijiwa S; Masutani C; Hanaoka F; Iwai S; Kuraoka I
Carcinogenesis; 2010 Mar; 31(3):388-93. PubMed ID: 20015866
[TBL] [Abstract][Full Text] [Related]
20. DNA polymerase ζ is a major determinant of resistance to platinum-based chemotherapeutic agents.
Sharma S; Shah NA; Joiner AM; Roberts KH; Canman CE
Mol Pharmacol; 2012 Jun; 81(6):778-87. PubMed ID: 22387291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
